A perspective in European Radiology (7 October 2026) by prostate imaging researchers appraises published AI studies for detecting clinically significant prostate cancer on MRI, using six domains: limits of predictability, reference standard quality, cohort design and selection, benchmark and comparator validity, clinical deployment, and terminology. It anchors these to requirements the PI-RADS Steering Committee recently set for AI development and reporting in biopsy-naive men.
The authors argue that near-perfect reported accuracy often comes from design choices rather than better algorithms: enriched cohorts that exclude the hard cases, reference standards that only verify MRI-positive men, pathway bias where AI and biopsy decisions are entangled, and comparisons against readers working under artificial conditions.
This matters because AI products for prostate MRI are being marketed and procured now. A department choosing one needs to judge the evidence behind it, not just the headline AUC.
- Ask whether the validation cohort was biopsy-naive men from a routine pathway, not an enriched set
- Check that MRI-negative men had a credible reference standard, not just no biopsy
- Look for comparison with radiologists under normal reporting conditions
- Require external validation on scanners and protocols like your own before deployment
- Be cautious of any reported AUC close to 1.0
Why it matters
Procurement decisions on AI are being made on headline accuracy that may not survive routine practice.
Don't overread it
A perspective piece, not a systematic review; it does not grade individual products.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for radiology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free